JP7423523B2 - ディフェンシンによる移植片対宿主病の予防と治療 - Google Patents

ディフェンシンによる移植片対宿主病の予防と治療 Download PDF

Info

Publication number
JP7423523B2
JP7423523B2 JP2020528244A JP2020528244A JP7423523B2 JP 7423523 B2 JP7423523 B2 JP 7423523B2 JP 2020528244 A JP2020528244 A JP 2020528244A JP 2020528244 A JP2020528244 A JP 2020528244A JP 7423523 B2 JP7423523 B2 JP 7423523B2
Authority
JP
Japan
Prior art keywords
defensin
human
defensins
hbd2
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020528244A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504348A (ja
JP2021504348A5 (https=
Inventor
ノーキルド，ペーター
Original Assignee
ディフェンシン セラピューティクス エーピーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディフェンシン セラピューティクス エーピーエス filed Critical ディフェンシン セラピューティクス エーピーエス
Publication of JP2021504348A publication Critical patent/JP2021504348A/ja
Publication of JP2021504348A5 publication Critical patent/JP2021504348A5/ja
Application granted granted Critical
Publication of JP7423523B2 publication Critical patent/JP7423523B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2020528244A 2017-11-24 2018-11-21 ディフェンシンによる移植片対宿主病の予防と治療 Active JP7423523B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17203527 2017-11-24
EP17203527.1 2017-11-24
EP18191954.9 2018-08-31
EP18191954 2018-08-31
PCT/EP2018/082022 WO2019101773A2 (en) 2017-11-24 2018-11-21 Prevention and treatment of graft-versus-host-disease with defensins

Publications (3)

Publication Number Publication Date
JP2021504348A JP2021504348A (ja) 2021-02-15
JP2021504348A5 JP2021504348A5 (https=) 2022-01-04
JP7423523B2 true JP7423523B2 (ja) 2024-01-29

Family

ID=64308771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020528244A Active JP7423523B2 (ja) 2017-11-24 2018-11-21 ディフェンシンによる移植片対宿主病の予防と治療

Country Status (15)

Country Link
US (1) US20200291082A1 (https=)
EP (1) EP3713590B1 (https=)
JP (1) JP7423523B2 (https=)
KR (1) KR20200097251A (https=)
CN (1) CN111741762A (https=)
AU (1) AU2018371948A1 (https=)
BR (1) BR112020010180A2 (https=)
CA (1) CA3083315A1 (https=)
ES (1) ES3038390T3 (https=)
MX (1) MX2020005370A (https=)
PL (1) PL3713590T3 (https=)
RU (1) RU2020116903A (https=)
SG (1) SG11202004207VA (https=)
WO (1) WO2019101773A2 (https=)
ZA (1) ZA202002669B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
KR20230112561A (ko) * 2022-01-20 2023-07-27 가톨릭대학교 산학협력단 간이식환자 장내균총 분석과 이를 통한 이식상태 모니터링과 면역조절 테라그노시스 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014523906A (ja) 2011-07-08 2014-09-18 ディフェンシン セラピューティクス アンパルトセルスカブ 炎症性腸疾患の経口治療
WO2017129195A1 (en) 2016-01-26 2017-08-03 Defensin Therapeutics Aps Methods for modulating intestinal microbiota

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
NZ540506A (en) * 2002-12-19 2008-09-26 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
WO2009113065A1 (en) * 2008-03-13 2009-09-17 Hadasit Medical Research Services & Development Ltd. Immuno-modulating compositions for the treatment of immune-mediated disorders
SG172709A1 (en) 2008-07-18 2011-07-28 Novozymes Adenium Biotech As Treatment of inflammatory bowel diseases with mammal beta defensins
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
WO2016086161A1 (en) * 2014-11-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Intestinal microbiota and gvhd
CN104971343B (zh) * 2015-07-13 2018-02-02 韩源平 防御素在制备治疗代谢综合征药物方面的应用
MX2020004863A (es) * 2017-11-10 2020-10-14 Defensin Therapeutics Aps Maduracion de la defensa de la mucosa y/o funcion intestinal/pulmonar en el bebe prematuro.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014523906A (ja) 2011-07-08 2014-09-18 ディフェンシン セラピューティクス アンパルトセルスカブ 炎症性腸疾患の経口治療
WO2017129195A1 (en) 2016-01-26 2017-08-03 Defensin Therapeutics Aps Methods for modulating intestinal microbiota

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Allergy & Asthma Proceedings，2004年，vol.25,p297-304
blood，2012年，120(21),SCI-50
Bone Marrow Transplantation，1998年，22,402-403
Disease Models & Mechanisms，2011年，4(3),p318-333

Also Published As

Publication number Publication date
KR20200097251A (ko) 2020-08-18
JP2021504348A (ja) 2021-02-15
PL3713590T3 (pl) 2025-09-15
RU2020116903A3 (https=) 2022-04-08
SG11202004207VA (en) 2020-06-29
CA3083315A1 (en) 2019-05-31
WO2019101773A2 (en) 2019-05-31
WO2019101773A3 (en) 2019-07-04
MX2020005370A (es) 2020-10-19
AU2018371948A1 (en) 2020-06-11
EP3713590C0 (en) 2025-05-07
ES3038390T3 (en) 2025-10-13
CN111741762A (zh) 2020-10-02
RU2020116903A (ru) 2021-12-24
US20200291082A1 (en) 2020-09-17
EP3713590B1 (en) 2025-05-07
ZA202002669B (en) 2021-05-26
EP3713590A2 (en) 2020-09-30
BR112020010180A2 (pt) 2021-01-12

Similar Documents

Publication Publication Date Title
US20230067261A1 (en) Methods for treating inflammatory conditions of the lungs
US20250009844A1 (en) Maturation of mucosal defense and gut/lung function in the preterm infant
JP7423523B2 (ja) ディフェンシンによる移植片対宿主病の予防と治療
US20080242615A1 (en) Surfactant protein-d for prevention and treatment of lung infections and sepsis
AU2015212357B2 (en) Tolerogenic compositions comprising and uses thereof
JP2002530083A (ja) 感染におけるリゾチーム融合タンパク質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200814

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20200709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230914

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231011

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240117

R150 Certificate of patent or registration of utility model

Ref document number: 7423523

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150